Publications by authors named "Marco Germani"

Claim this Profile
F
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.
Carlotta Antoniotti, Federica Marmorino, Daniele Rossini, Hans Joachim Schmoll, Sara Lonardi, Marco Maria Germani

Eur J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.
Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, Yoshiaki Nakamura, Simone Oldani

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncotype DX in clinical practice: impact on treatment decisions and healthcare system economy.
Alessia Capozzi, Silvia Maria Rossi, Giovanna Sabarese, Marco Germani, Gabriella Gullotta

Pathologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Clinical experience with encorafenib and cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer after early relapse following adjuvant chemotherapy].
Vincenzo Formica, Marco Maria Germani, Giulia Piacentini, Elena Traverso, Chiara Cremolini

Recenti Prog Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.
R Moretto, D Rossini, Mariam Grazia Polito, Carlotta Antoniotti, Rossana Intini, Marco Maria Germani

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer.
Roberto Moretto, Marco Maria Germani, Martina Carullo, Veronica Conca, Alessandro Minelli

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of depth of response and early tumour shrinkage in patients with -mutated metastatic colorectal cancer treated with targeted therapy.
Guglielmo Vetere, Marco Maria Germani, Carlotta Antoniotti, Lisa Salvatore, Filippo Pietrantonio

Ther Adv Med Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration.
Roberto Moretto, Daniele Rossini, Sabina Murgioni, Paolo Ciracì, Vincenzo Nasca, Marco Maria Germani

JCO Precis Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Artificial Intelligence on Tumor Boards: Perspectives from Surgeons, Medical Oncologists and Radiation Oncologists.
Valerio Nardone, Federica Marmorino, Marco Maria Germani, Natalia Cichowska-Cwalińska, Vittorio Salvatore Menditti

Curr Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
Marco Maria Germani, Guglielmo Vetere, Mirella Giordano, Paolo Ciracì, Iolanda Capone

Front Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma.
Marco Maria Germani, Chiara Boccaccio, Antonio Matrone, Eleonora Molinaro, Greta Alì

Oncologist· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, Filippo Ghelardi, Maria Caterina De Grandis, Marco Maria Germani

Eur J Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.
Beatrice Borelli, Stefania Crucitta, Alessandra Boccaccino, Maria Antista, Carlotta Antoniotti, Marco Maria Germani

Tumori· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors.
Claire Gallois, Matteo Landi, Julien Taieb, Marine Sroussi, Bahar Saberzadeh-Ardestani, Marco Maria Germani

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Impact of Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable -Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy.
Roberto Moretto, Marco Maria Germani, Javier Ros, Francesca Daniel, Filippo Ghelardi

JCO Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Paolo Manca, Francesca Corti, Rossana Intini, Giacomo Mazzoli, Rosalba Miceli, Marco Maria Germani

Eur J Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm.
Beatrice Borelli, Marco Maria Germani, Martina Carullo, Roberto Mattioni, Bruno Manfredi

Crit Rev Oncol Hematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Roberto Moretto, Marco Maria Germani, Mirella Giordano, Veronica Conca, Agnese Proietti

Br J Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF metastatic colorectal cancer.
Elena Elez, Javier Ros, Jose Fernández, Guillermo Villacampa, Ana Belén Moreno-Cárdenas, Marco Maria Germani

Nat Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability.
Beatrice Borelli, Carlotta Antoniotti, Martina Carullo, Marco Maria Germani, Veronica Conca

Cancers (Basel)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients.
Marco Maria Germani, Martina Carullo, Alessandra Boccaccino, Veronica Conca, Gianluca Masi

Cancers (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Daniele Rossini, Marco M Germani, Sara Lonardi, Filippo Pietrantonio, Emanuela Dell'Aquila

Eur J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features.
Marco Maria Germani, Beatrice Borelli, Piero Boraschi, Carlotta Antoniotti, Clara Ugolini

Cancer Treat Rev· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
Carlotta Antoniotti, Marco M Germani, Daniele Rossini, Sara Lonardi, Filippo Pietrantonio

Eur J Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative Ultraselection of Patients With / Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.
Giovanni Randon, Giulia Maddalena, Marco Maria Germani, Chiara Carlotta Pircher, Paolo Manca

JCO Precis Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis